Pricing Log in Create free account
Saturday 17 October 2026 Export RKDA’s income statement to Excel — free account

Arcadia Biosciences, Inc.

RKDA Consumer Defensive Packaged Foods

Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 35.9% and free cash flow grew 82.1%, each against the same quarter a year earlier.

0.16 0.04 −20.00%
Market cap
$490.0K
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
3/9
Altman Z
−59.20
Beneish M
−1.84
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 32.18%

Capital & Financial Ratios $m

Market Cap 0.49
Revenue 4.75
Net Income (11.13)
Free Cash Flow (2.54)
Net Debt (4.18)
Current Ratio 3.49 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.51) (negative: loss-making)
P/S ratio 0.10
P/B ratio 0.76
Past 5Y EPS Growth —
This Y EPS Growth 19.24% (at or above 15%: strong)
Next Y EPS Growth 5.47%
Next Y revenue growth 58.50% (at or above 10%: strong)
Next 5Y EPS Growth 49.05% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.8×, against a ten-year median of 0.4×; over the ten years it ranged from −5.7× in 2019 to 21.8× in 2020.
P/S against its own 10 years 0.04%
10-year low 10-year high
P/B against its own 10 years 30.37%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 12 4 5 4
Receivables 1 1 0 1
Inventory 1 1 1 1
Other 0 — — —
15 9 6 6
2023 2024 2025 Q'26
Payables 2 2 2 1
ST’ Debt — — — —
Other 0 0 0 0
4 3 2 2

Compound Annual Growth %

10y 5y 3y
Sales (1.08%) (9.57%) (13.16%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (20.34%) (32.04%) (41.71%)

Revenue $m

Mar Jun Sep Dec Year
’26 1 1 — — —
’25 1 1 1 1 5
’24 1 1 2 1 5
’23 1 1 1 1 4
’22 3 4 2 (1) 7
’21 1 1 2 2 7
’20 0 0 0 7 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 0 — — —
’25 (2) (2) 0 (1) (5)
’24 (3) (2) (2) (2) (10)
’23 (3) (5) (3) (4) (15)
’22 (5) (3) (3) (2) (14)
’21 (5) (6) (8) (7) (26)
’20 (9) (7) (7) (7) (30)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 0 — — —
’25 (1) (2) 0 0 (4)
’24 (3) (2) (2) 2 (5)
’23 (3) (5) (3) (4) (15)
’22 (4) (3) (3) (2) (13)
’21 (5) (6) (8) (7) (27)
’20 (10) (8) (7) (7) (33)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.11) (2.09) — — —
’25 1.90 (3.26) 0.62 (0.98) (1.71)
’24 (1.78) 0.78 (1.18) (2.98) (5.17)
’23 (10.86) 0.61 (1.89) (2.10) (11.30)
’22 (8.00) (6.80) (4.80) (6.31) (25.65)
’21 4.40 (9.60) (4.00) (16.80) (27.60)
’20 11.60 (41.60) (24.00) 36.00 (18.80)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 688.00 144.00 105.80 72.80 92.00 38.88 10.36 2.60 1.85 1.76

Analyst estimates 2026–2028

Powerpack
High 2,736.00 944.00 2,662.40 416.00 259.20 256.00 106.40 18.94 10.31 6.71
People
People Employees 57 42 24 61 11 11 30 21 9 8
Revenue/emp, $m 0.06 0.10 0.06 0.02 0.73 0.62 0.25 0.21 0.56 0.61
Income, $m
Income, $m Revenue 3 4 1 1 8 7 7 4 5 5
Gross margin, % 71.93 92.97 54.85 24.29 35.29 (28.44) 17.75 51.19 41.27 36.23
EBT (20) (16) (13) (29) (6) (16) (11) (5) (4) (2)
EBT margin, % (614.77) (389.49) (920.08) (2,469.72) (76.55) (237.94) (145.78) (119.47) (85.41) (47.98)
Net income (20) (16) (13) (29) (6) (16) (16) (14) (7) (2)
Depreciation 0 0 0 1 2 7 2 1 1 0
Per share, $
Per share, $ Revenue 57.44 74.69 15.54 7.35 32.27 12.74 12.38 3.60 3.70 3.55
Earnings (352.00) (291.20) (143.20) (181.20) (18.80) (27.60) (25.65) (11.30) (5.17) (1.71)
Cash flow (307.30) (259.09) (144.70) (108.10) (121.36) (48.62) (23.33) (12.36) (7.06) (3.46)
Capex (4.16) (1.39) (2.55) (9.18) (9.35) (1.86) 1.42 0.09 3.17 0.55
Free cash flow (311.46) (260.48) (147.25) (117.28) (130.70) (50.48) (21.92) (12.27) (3.90) (2.92)
Book value 399.96 148.55 136.04 52.33 114.67 58.64 34.89 10.27 4.57 3.03
Shares, m 0 0 0 0 0 1 1 1 1 1
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 12.53 2.89 8.16 29.83 3.14 3.26 0.90 0.81 1.60 0.56
P/B 1.80 1.45 0.93 4.19 0.88 0.71 0.32 0.28 1.30 0.65
EV/Sales 4.56 4.89 7.64 8.28 0.35 (0.95) (1.86) (1.78) 0.78 (0.36)
EV/FCF (0.84) (1.40) (0.81) (0.52) (0.09) 0.24 1.05 0.52 (0.42) (1.61)
Cash, $m
Cash, $m Operating cash flow (17) (14) (14) (17) (30) (26) (14) (15) (10) (5)
Capex 0 0 0 (1) (2) (1) 1 0 4 1
Free cash flow (17) (14) (14) (19) (33) (27) (13) (15) (5) (4)
Balance, $m
Balance, $m Working capital 49 12 20 23 25 30 21 11 7 4
Total debt 25 — — 0 3 3 2 — — —
Net debt (25) (13) (22) (25) (22) (29) (21) (12) (4) (5)
Shareholders’ equity 22 8 13 8 29 31 21 13 6 4
Returns, %
Returns, % ROA (30.00) (42.95) (66.41) (101.79) (11.65) (32.13) (42.22) (57.50) (42.37) (23.32)
ROIC 0.00 0.00 0.00 0.00 (130.26) (884.26) (3,419.68) (359.45) (115.09) 0.00
ROE (62.87) (104.00) (129.48) (272.50) (25.25) (49.07) (59.03) (83.21) (74.37) (45.14)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Arcadia Biosciences, Inc. vs peers in Packaged Foods (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PAVS Paranovus Entertainment Technology Ltd. $2.9M — (loss-making) — (loss-making) −8.96% (below 0%: shrinking) −582.47% (below 0%: shrinking) +88.21% (above 0%: growing) 5.59% 0.00% Compare
ORISF Oriental Rise Holdings Limited $2.3M — — — — −105.36% (below 0%: shrinking) — — Compare
RGFC Real Good Food Company, Inc. $2.2M — (loss-making) — (loss-making) +47.98% (above 0%: growing) n/m +84.37% (above 0%: growing) 20.85% (15.95%) Compare
MEHA Functional Brands Inc. $1.9M — (loss-making) — +2.07% (above 0%: growing) n/m −209.98% (below 0%: shrinking) 59.89% (70.59%) Compare
ATPC Agape ATP Corporation $1.7M 1.2× — −93.38% (below 0%: shrinking) n/m +77.69% (above 0%: growing) 86.13% (4,021.90%) Compare
CYAN Cyanotech Corporation $1.7M — (loss-making) 2.4× +11.12% (above 0%: growing) n/m +204.00% (above 0%: growing) 42.38% 7.00% Compare
BSFCD Blue Star Foods Corp. $960.0K 14.2× 2.3× −54.59% (below 0%: shrinking) n/m −123.09% (below 0%: shrinking) 55.80% (29.04%) Compare
STKH Steakholder Foods Ltd. Sponsored ADR $670.0K — (loss-making) — — n/m +35.62% (above 0%: growing) 0.00% 0.00% Compare
RKDA Arcadia Biosciences, Inc. $490.0K — (loss-making) — (loss-making) −0.82% (below 0%: shrinking) n/m +82.11% (above 0%: growing) 43.73% (34.37%)
Median of peers $1.8M — — −3.44% — +56.66% 42.38% (15.95%)

All 71 Packaged Foods stocks →

Arcadia Biosciences, Inc. (RKDA) key facts

  • Concern: Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024.
  • Concern: Arcadia Biosciences, Inc. reported a net loss of $2.3 million, or a loss of $1.71 per share, for fiscal 2025.
  • Arcadia Biosciences, Inc. (RKDA) is a Packaged Foods company in the Consumer Defensive sector, listed on Nasdaq.
  • As of October 16, 2026, RKDA traded at $0.16, a market capitalization of $490,000.00.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.1× sales.
  • Return on equity was −45.1% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −59.20 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Arcadia Biosciences, Inc. (RKDA) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/RKDA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com